Editorial Volume 12, Issue 17 pp 16665—16666
Mitochondrial oxidative phosphorylation is linked to T-cell exhaustion
How to Cite
Mounting evidence indicates that metabolic reprogramming is not only a hallmark of tumor cells, but also critical for various immune cells, including T cells . Studies of immunometabolism demonstrate that the functional roles of T-cell subsets are linked to different metabolic pathways and key factors (e.g., metabolic enzymes and metabolites), which can modulate T-cell development, differentiation, and activation . In certain pathological settings, such as tumors, T-cell populations called “exhausted T cells” are unable to exert their functional roles. This phenomenon is similar to observations in chronic viral infection; however, the underlining molecular mechanism and its corresponding metabolic alterations remains unclear. It is presently unknown how repetitive antigen challenge leads to T-cell exhaustion, as exhibited by self-renewal ability failure. Thus, there is substantial interest in elucidating how metabolism represents a key link to T-cell exhaustion.
In the new research article “Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen” , Dr. Thompson’s group at Memorial Sloan Kettering Cancer Center characterized the role of metabolic reprogramming in T-cell exhaustion using mouse models of melanoma (Figure 1). They found that persistent antigen challenge led to a shift in metabolic reprogramming, which was critical for restricting T-cell self-renewal and proliferation. The authors observed that exhausted T cells exhibited higher glycolysis, impaired mitochondrial functions, and lower nucleotide biosynthesis. Further characterizing the molecular mechanism of mitochondrial dysfunction in exhausted T cells, they detected significantly enhanced activity of the key regulator of T-cell exhaustion NFAT, and demonstrated that antigen-induced ROS activity was tightly linked to T-cell exhaustion. Moreover, they proved that antioxidant treatment restored metabolic T-cell function and self-renewal in exhausted T cells during chronic antigen stimulation, both in vitro and in vivo. This study highlights that oxidative force is an aftereffect of chronic antigen-driven mitochondrial dysfunction, which can diminish T-cell proliferation and self-renewal capacities in vitro and in vivo, suggesting that treatment with a functional sustaining redox balance may restore T cells from “exhausted” to “effective” status.
Previous studies have emphasized the need to further characterize key factors controlling T-cell exhaustion to guide the development of future therapy to enhance anti-tumor immunity. Well-established examples include CTLA-4, PD-1, B7-H4, and CD28 . For example, CD28 signaling can enhance glycolytic flux to satisfy the metabolic needs for T-cell activation , whereas PD-1 and CTLA-4 signaling impede T-cell activation by impairing glucose uptake . Overcoming the restriction of T-cell exhaustion would be another critical means of enhancing anti-tumor therapy. In the new study, Vardhana et al.  additionally characterized how metabolic alterations influence exhausted T cells, and demonstrated that antioxidants such as N-acetylcysteine could reverse exhausted T-cell capacity and preserve anti-tumor T-cell responsiveness in vivo. Unrestrained oxidative stress can result in protein and/or DNA destruction in cancer cells, and antioxidants (e.g., vitamin C and selenium) have been extensively utilized to counter these effects in cancer. However, vitamin C reportedly enhances the expansion of regulatory T cells (Tregs) , which decreases anti-tumor immunity. It is possible that N-acetylcysteine could exert side-effects on other immune cell subsets, such as Tregs and dendritic cells (DCs). Thus, it is warranted to further dissect the global alterations of immunity during N-acetylcysteine treatment. Ideally, further research will yield an optimal synergy strategy for boosting anti-tumor immunity against melanoma.
T-cell exhaustion is also reported in patients with hepatitis B virus (HBV) and hepatitis C virus (HCV), and it is unknown whether this occurrence is related to a metabolic mechanism. It would be interesting to analyze exhausted HBV-specific CD8+ T cells by liquid chromatography–mass spectrometry (LC–MS) and single-cell RNA sequencing. Non-coding RNAs, such as microRNA-155, reportedly regulate exhausted CD8+ T cells in models of chronic lymphocytic choriomeningitis virus (LCMV) infection . It remains unclear how NFAT is modulated in exhausted T cells, and whether microRNA is involved in this process. Several potential microRNAs are predicted to target NFAT1, including microRNA-137 and microRNA-30-5p. Future studies are needed to examine how N-acetylcysteine alters microRNA expressions, and how NFAT and the transcription factor TOX are regulated in exhausted T cells.
The new work by Vardhana et al.  connects mitochondrial dysfunction to exhausted T cells using in vitro chronic antigen stimulation and in vivo mouse models. Their findings indicate a potential new strategy for enhancing anti-tumor immunity against melanoma. Since PD-1/PD-L1 targeting has been utilized in triple-negative breast cancer (TNBC), the murine TNBC cell line 4T1 might be useful for testing the link between mitochondrial oxidative phosphorylation and self-renewal of exhausted T cells upon persistent antigen challenge in future research.
This study is supported by Louisiana State University (LSU) Feist-Weiller Cancer Center (FWCC) Legacy Funds (149741373A), Intramural Research Council Support (110251225A), and the Micro Seed Funds.
- 1. Patel CH, et al. Nat Rev Drug Discov. 2019; 18:669–88. https://doi.org/10.1038/s41573-019-0032-5 [PubMed]
- 2. Buck MD, et al. J Exp Med. 2015; 212:1345–60. https://doi.org/10.1084/jem.20151159 [PubMed]
- 3. Vardhana SA, et al. Nat Immunol. 2020; 21:1022–33. https://doi.org/10.1038/s41590-020-0725-2 [PubMed]
- 4. Waldman AD, et al. Nat Rev Immunol. 2020. https://doi.org/10.1038/s41577-020-0306-5 [PubMed]
- 5. Frauwirth KA, et al. Immunity. 2002; 16:769–77. https://doi.org/10.1016/S1074-7613(02)00323-0 [PubMed]
- 6. Intlekofer AM, Thompson CB. J Leukoc Biol. 2013; 94:25–39. https://doi.org/10.1189/jlb.1212621 [PubMed]
- 7. Oyarce K, et al. Front Immunol. 2018; 9:112. https://doi.org/10.3389/fimmu.2018.00112 [PubMed]
- 8. Stelekati E, et al. Cell Rep. 2018; 23:2142–56. https://doi.org/10.1016/j.celrep.2018.04.038 [PubMed]